🚀 VC round data is live in beta, check it out!
Biovica International Valuation Multiples
Discover revenue and EBITDA valuation multiples for Biovica International and similar public comparables like Mainz Biomed, Bionano Genomics, Glycorex Transplantation, NRGene and more.
Biovica International Overview
About Biovica International
Biovica International AB is a biotech company. The company develops and commercializes blood-based diagnostic tests with biomarkers that improve the monitoring and evaluation of modern cancer treatments. The company promotes healthcare through collaboration with cancer institutes and pharmaceutical companies. DiviTum is manufactured by the company and sold as a kit consisting of a reaction plate with reagents that have been optimized for ELISA applications.
Founded
2009
HQ
Employees
26
Website
Financials (LTM)
EV
$794K
Biovica International Financials
Biovica International reported last 12-month revenue of $1M and negative EBITDA of ($8M).
In the same LTM period, Biovica International generated ($8M) in EBITDA losses and had net loss of ($8M).
Revenue (LTM)
Biovica International P&L
In the most recent fiscal year, Biovica International reported revenue of $917K and EBITDA of ($8M).
Biovica International expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $1M | XXX | $917K | XXX | XXX | XXX |
| Gross Profit | — | XXX | $860K | XXX | XXX | XXX |
| Gross Margin | — | XXX | 94% | XXX | XXX | XXX |
| EBITDA | ($8M) | XXX | ($8M) | XXX | XXX | XXX |
| EBITDA Margin | (586%) | XXX | (874%) | XXX | XXX | XXX |
| EBIT Margin | (631%) | XXX | (974%) | XXX | XXX | XXX |
| Net Profit | ($8M) | XXX | ($9M) | XXX | XXX | XXX |
| Net Margin | (623%) | XXX | (994%) | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Biovica International Stock Performance
Biovica International has current market cap of $11M, and enterprise value of $794K.
Market Cap Evolution
Biovica International's stock price is $0.04.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $794K | $11M | -1.3% | XXX | XXX | XXX | $-0.03 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialBiovica International Valuation Multiples
Biovica International trades at 0.6x EV/Revenue multiple, and (0.1x) EV/EBITDA.
EV / Revenue (LTM)
Biovica International Financial Valuation Multiples
As of March 21, 2026, Biovica International has market cap of $11M and EV of $794K.
Equity research analysts estimate Biovica International's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Biovica International has a P/E ratio of (1.3x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $11M | XXX | $11M | XXX | XXX | XXX |
| EV (current) | $794K | XXX | $794K | XXX | XXX | XXX |
| EV/Revenue | 0.6x | XXX | 0.9x | XXX | XXX | XXX |
| EV/EBITDA | (0.1x) | XXX | (0.1x) | XXX | XXX | XXX |
| EV/EBIT | (0.1x) | XXX | (0.1x) | XXX | XXX | XXX |
| EV/Gross Profit | — | XXX | 0.9x | XXX | XXX | XXX |
| P/E | (1.3x) | XXX | (1.2x) | XXX | XXX | XXX |
| EV/FCF | — | XXX | (0.1x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Biovica International Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Biovica International Margins & Growth Rates
Biovica International's revenue in the last 12 month grew by 190%.
Biovica International's revenue per employee in the last FY averaged $0.1M.
Biovica International's rule of 40 is (397%) (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Biovica International's rule of X is (113%) (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Biovica International Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 190% | XXX | 55% | XXX | XXX | XXX |
| EBITDA Margin | (586%) | XXX | (874%) | XXX | XXX | XXX |
| EBITDA Growth | (29%) | XXX | (0%) | XXX | XXX | XXX |
| Rule of 40 | — | XXX | (397%) | XXX | XXX | XXX |
| Bessemer Rule of X | — | XXX | (113%) | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.1M | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 1116% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Biovica International Public Comps
See public comps and valuation multiples for other Diagnostics & Genomics comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Mainz Biomed | XXX | XXX | XXX | XXX | XXX | XXX |
| Bionano Genomics | XXX | XXX | XXX | XXX | XXX | XXX |
| Glycorex Transplantation | XXX | XXX | XXX | XXX | XXX | XXX |
| NRGene | XXX | XXX | XXX | XXX | XXX | XXX |
| 2cureX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Biovica International M&A Activity
Biovica International acquired XXX companies to date.
Last acquisition by Biovica International was on XXXXXXXX, XXXXX. Biovica International acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Biovica International
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialBiovica International Investment Activity
Biovica International invested in XXX companies to date.
Biovica International made its latest investment on XXXXXXXX, XXXXX. Biovica International invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Biovica International
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Biovica International
| When was Biovica International founded? | Biovica International was founded in 2009. |
| Where is Biovica International headquartered? | Biovica International is headquartered in Sweden. |
| How many employees does Biovica International have? | As of today, Biovica International has over 26 employees. |
| Is Biovica International publicly listed? | Yes, Biovica International is a public company listed on Nasdaq Stockholm. |
| What is the stock symbol of Biovica International? | Biovica International trades under BIOVIC B ticker. |
| When did Biovica International go public? | Biovica International went public in 2017. |
| Who are competitors of Biovica International? | Biovica International main competitors are Mainz Biomed, Bionano Genomics, Glycorex Transplantation, NRGene. |
| What is the current market cap of Biovica International? | Biovica International's current market cap is $11M. |
| What is the current revenue of Biovica International? | Biovica International's last 12 months revenue is $1M. |
| What is the current revenue growth of Biovica International? | Biovica International revenue growth (NTM/LTM) is 190%. |
| What is the current EV/Revenue multiple of Biovica International? | Current revenue multiple of Biovica International is 0.6x. |
| Is Biovica International profitable? | No, Biovica International is not profitable. |
| What is the current EBITDA of Biovica International? | Biovica International has negative EBITDA and is not profitable. |
| What is Biovica International's EBITDA margin? | Biovica International's last 12 months EBITDA margin is (586%). |
| What is the current EV/EBITDA multiple of Biovica International? | Current EBITDA multiple of Biovica International is (0.1x). |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.